- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07836101
Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events (IRIS)
Phase II Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events (The IRIS Trial: Immune Checkpoint Inhibitor Rechallenge Involving Sarilumab)
The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the patient's treating physician. Patients will be sequentially enrolled into the single-arm study after meeting the pre-specified eligibility criteria
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Danielle Wendler
- Telefoonnummer: 410-502-5140
- E-mail: JHCTN@jhmi.edu
Studie Contact Back-up
- Naam: Chelsea Miralles
- Telefoonnummer: 410-955-9923
- E-mail: cmirall1@jhmi.edu
Studie Locaties
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
Contact:
- Danielle Wendler
- Telefoonnummer: 410-502-5140
- E-mail: JHCTN@jhmi.edu
-
Contact:
- Chelsea Miralles
- Telefoonnummer: 4109559923
- E-mail: cmirall1@jhmi.edu
-
Hoofdonderzoeker:
- Aliyah Pabani, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Eligible patients include patients with malignancy treated with ICI, who have been diagnosed with a clinically significant irAE (grade 1-3 attributed to ICI per CTCAE v6.0) requiring interruption of ICI by the treating physician. This study is limited to patients with the following specific irAEs as IL-6R blockade has demonstrated effectiveness in these conditions. Specific toxicities eligible for inclusion are; arthritis, colitis, PMR, nephritis, pneumonitis, hepatitis, myositis
-
The risk/benefit profile must favor ICI rechallenge as deemed per treating oncologist
-
The irAE must have improved to grade 1 by CTCAE criteria v6.0 for at least 1 week (exception for patients who have endocrinopathies which will typically require lifelong hormone supplementation)
-
Be willing and able to provide informed consent/assent for the trial
-
Be ≥18 years of age on the day of signing informed consent
-
Female subject of childbearing potential must have a negative urine or serum pregnancy test within 2 weeks prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
-
Women of child-bearing potential (WOCBP):
- Agree to use contraception while participating in this study, and for a period of 6 months following last dose of Sarilumab or ICI, as effects of these agents on the developing human fetus are unknown. Men whose partner is a WOCBP must also agree to use contraception during this period. Negative pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within two weeks of registration. Women must not be breastfeeding or plan to breastfeed for the duration of therapy or 6 months after.
-
Males must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 3 months after last dose of sarilumab, 120 days even if he has undergone a successful vasectomy
-
Have adequate organ function as described below
- Absolute neutrophil count (ANC) ≥500/mm3
- Platelets ≥ 50,000/mm3
- AST/ALT <=3× institutional upper limit of normal
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Completed informed consent process, including signing Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent form.
-
Willing and able to comply with clinical trial instructions and requirements. Subjects must be competent to report AEs, understand the drug dosing schedule, and use of medications to control AEs
Exclusion Criteria:
- History of grade 4 irAE (attributed to ICI per CTCAE v6.0)
- History of cardiovascular or neurologic immune related adverse event
- Active or serious infections
- History of latent Tuberculosis (TB) or uncontrolled hepatitis B/C
- History of gastrointestinal perforation or diverticulitis
- Severe hepatic impairment (AST, ALT >3xULN; total bilirubin >1.5xULN)
- Significant hematological abnormalities
- On prednisone equivalent >10mg prior to first dose of trial treatment
- History of immunodeficiency disorder
- Treatment with a non-biologic immunosuppressive or immune-modulating drug (e.g. methotrexate, azathioprine, mycophenolate, cyclosporine, hydroxychloroquine, penicillamine) at time of enrollment
- Treatment with other immune-modulating biologic agents (e.g TNF-alpha inhibitors) within 8 weeks prior to enrollment
- History of anaphylaxis or IgE-mediated hypersensitivity to sarilumab or history of allergic reactions attributed to compounds of similar chemical or biologic composition to sarilumab.
- The subject must meet all of the inclusion criteria and none of the exclusion criteria.
No eligibility waivers will be granted.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Sarilumab with ICI
Sarilumab is dosed 200 mg subcutaneously every two weeks for a total of 24 weeks. ICI will be dosed by investigator's choice per standard of care for malignancy. ICI will be administered on day 1 of each 3 or 4 week cycle depending on the selected ICI agent. Administration of ICI will continue past the 24 week timepoint per discretion of the investigator. |
Sarilumab is dosed 200 mg subcutaneously every two weeks for a total of 24 weeks. ICI will be administered on day 1 of each 3 or 4 week cycle depending on the selected ICI agent. Administration of ICI will continue past the 24 week timepoint per discretion of the investigator. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety as assessed by Absence of any grade ≥2 Immune Related Adverse Event (irAE)
Tijdsspanne: From enrollment to the end of treatment at 53 weeks
|
Absence of any grade ≥2 Immune Related Adverse Event (irAE) in the 3 months after ICI rechallenge, defined as grade ≥2 adverse event attributed to ICI by CTCAE v6.0 |
From enrollment to the end of treatment at 53 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety and tolerability as assessed by occurrence of adverse events
Tijdsspanne: From enrollment to the end of treatment at 53 weeks
|
Safety and tolerability will be measured by occurrence of grade ≥3 adverse events as measured by CTCAE v6.0 and patient reported outcomes (PROs) as assessed by PRO-CTCAE v1.0. |
From enrollment to the end of treatment at 53 weeks
|
|
Absence of Serious immune-related adverse event
Tijdsspanne: From enrollment to the end of treatment at 53 weeks
|
To assess to the safety of Immune Checkpoint Inhibitor (ICI) rechallenge with sarilumab with respect to serious irAE of grade ≥2 in patients with a history of non- cardiovascular and non-neurologic clinically significant irAEs. |
From enrollment to the end of treatment at 53 weeks
|
|
Efficacy as assessed by progression free survival
Tijdsspanne: From enrollment to the end of treatment at 53 weeks
|
Cancer outcomes will be measured by progression free survival (PFS). PFS is defined as the time from first dose of sarilumab + ICI rechallenge until investigator-assessed radiological progressive disease (PD) or death, whichever comes first. |
From enrollment to the end of treatment at 53 weeks
|
|
Efficacy as assessed by Overall survival
Tijdsspanne: From enrollment to the end of treatment at 53 weeks
|
Cancer outcomes will be measured by overall survival (OS).Overall survival is defined as the time from first dose of sarilumab + ICI rechallenge until death. |
From enrollment to the end of treatment at 53 weeks
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Aliyah Pabani, MD, Johns Hopkins University
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- J2687
- 15845 (Ander subsidie-/financieringsnummer: Robert A. Winn Excellence in Clinical Trials Award)
- IRB00559848 (Andere identificatie: Johns Hopkins IRB)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .